Abstract
We determined the characteristics of posttransplant tuberculosis and the impact of rifampin-based antituberculosis regimens on outcomes in the current era. Patients comprised 64 transplant recipients with tuberculosis, divided into 2 consecutive cohorts: an earlier cohort (cases occurring from 2003 to 2007) and a later cohort (cases from 2008 to 2011). Patients from the later versus earlier era had tuberculosis develop later after transplant (odds ratio, 1.01; 95% CI, 1.00–1.02; P = .05), were more likely to be liver transplant recipients (odds ratio, 4.52; 95% CI, 1.32–15.53; P = .02), and were more likely to receive tacrolimus-based immunosuppression (odds ratio, 3.24; 95% CI, 1.14–9.19; P = .03). Mortality rate was 10% in the later cohort and 21% in the earlier cohort (P = .20). Rifampin-based treatment was less likely to be used in patients with prior rejection (P = .04). However, neither rejection rate (P = .71) nor mortality (P = .93) after tuberculosis differed between recipients who received rifampin and recipients who did not. Thus, notable changes have occurred in the epidemiological characteristics of tuberculosis in transplant recipients. Overall mortality rate has improved, with about 90% of the patients now surviving after tuberculosis.
Get full access to this article
View all access options for this article.